Keytruda Approved for Some Patients With Gastric Cancer
BY Jason M. Broderick
Keytruda (pembrolizumab) was granted FDA approval for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received two or more lines of chemotherapy and are PD-L1-positive.
New Treatments Needed for Those Disabled by Advanced Gastric Cancer
BY Brielle Urciuoli
Patients with advanced gastric cancer tend to use their health care resources more often and have a worse quality of life than those without the disease
Will There Be an Immunotherapy Approval in Gastric Cancer?
BY Silas Inman
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
Keytruda Granted Priority Review for Advanced Gastric Cancer
BY Jason Harris
Keytruda (pembrolizumab) was granted a priority review to a supplemental biologics license application for the treatment of patients with recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have undergone at least two courses of chemotherapy.
New Advances in Gastroesophageal Cancers
BY Gina Columbus
Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.
Improving Quality of Life and Food Intake in Gastric Cancer
BY Wayne Kuznar
Surgical palliation improved quality of live and solid food intake in patients with certain types of gastric cancer, according to a recent study.
Opdivo Improves Survival in Patients With Gastric Cancer
BY Silas Inman
A recent study found that Opdivo improves survival in patients with gastric or gastroesophageal junction (GEJ) cancer. 
Immunotherapy Continues to Show Promise in Treating Gastric Cancers
BY Laura Panjwani
The JAVELIN trial showed that many patients with gastric cancer could benefit from immunotherapy. 
In Gastroesophageal Cancers, Better Prevention and Treatments Needed
BY Debu Tripathy, MD
Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.
Medical Illustration: Targeting HER2 in Gastric Cancer
BY Erin Moore
For about 20 percent of patients with advanced gastric cancer, tumors overproduce a receptor protein called HER2.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Gastric CURE discussion group.
Search Cancer Drugs & Terms
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Gastric Cancer Treatment (PDQ®)
Expert-reviewed information summary about the treatment of gastric cancer.
Prevention, Genetics, Causes
Information related to prevention, genetics, risk factors
Stomach (Gastric) Cancer Prevention (PDQ®)
Expert-reviewed information summary about factors that may influence the risk of developing stomach cancer and about research aimed at the prevention of this disease.
Screening and Testing
Information about methods of cancer detection including new imaging technologies, tumor markers, and biopsy procedures
Stomach (Gastric) Cancer Screening (PDQ®)
Expert-reviewed information summary about tests used to detect or screen for stomach (gastric) cancer.
//For side ad protocol